Business acquisition contingent consideration potential cash payments upon achievement of sales milestone.

No definition available.

Name:	bmrn_BusinessAcquisitionContingentConsiderationPotentialCashPaymentsUponAchievementOfSalesMilestone
Namespace Prefix:	bmrn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalty rate lower limit.

+ References

No definition available.

+ Details

Name:	bmrn_RoyaltyRateLowerLimit
Namespace Prefix:	bmrn_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Royalty rate upper limit.

+ References

No definition available.

+ Details

Name:	bmrn_RoyaltyRateUpperLimit
Namespace Prefix:	bmrn_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=bmrn_MerckSeronoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bmrn_PegvaliaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=bmrn_AAndRKuvanAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bmrn_FIRDAPSEMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LICENSE AND COLLABORATION AGREEMENTS (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023 USD ($)	Dec. 31, 2023 EUR (€)	Mar. 31, 2019
Merck Serono \| Pegvaliase Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Business acquisition, cash paid \| $	$ 125.0
Maximum \| Merck Serono \| A&R Kuvan Agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Business acquisition contingent consideration potential cash payments upon achievement of sales milestone \| €		€ 60.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations \| FIRDAPSE
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalties on net product sales, minimum			7.00%
Royalties on net product sales, maximum			10.00%